Fusion Pharmaceuticals (FUSN) Stock Price, News & Analysis

Company Overview

Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. The company's lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing that target insulin-like growth factor 1 receptor. It is conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, the company develops FPI-1966 for the treatment of multiple cancers, including colorectal, ovarian, bladder, and head and neck cancers.; FPI-2068, a bispecific antibody, which is in Phase 1 clinical trial targeting epidermal growth factor receptor, and mesenchymal epithelial transition factor. It has a strategic collaboration agreement with AstraZeneca UK Limited to discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. The company was incorporated in 2014 and is headquartered in Hamilton, Canada.

Key Stats

• Today's Range: $21.55 to $21.55
• 50-Day Range: $21.38 to $21.55
• 52-Week Range: $2.31 to $21.60
• Volume: N/A
• Average Volume: 1.69 million shs
• Market Capitalization: $1.83 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

FUSN Stock Analysis - Frequently Asked Questions

How were Fusion Pharmaceuticals' earnings last quarter?

Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) issued its quarterly earnings results on Tuesday, November, 9th. The company reported ($0.45) earnings per share for the quarter, topping analysts' consensus estimates of ($0.58) by $0.13. The business had revenue of $0.33 million for the quarter. Fusion Pharmaceuticals had a negative trailing twelve-month return on equity of 48.74% and a negative net margin of 4,136.55%.

When did Fusion Pharmaceuticals IPO?

Fusion Pharmaceuticals (FUSN) raised $126 million in an initial public offering (IPO) on Friday, June 26th 2020. The company issued 8,400,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, Jefferies and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What other stocks do shareholders of Fusion Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Fusion Pharmaceuticals investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Meta Platforms (META), Novo Nordisk A/S (NVO), Super Micro Computer (SMCI) and ServiceNow (NOW).

Company Calendar

• Last Earnings: 11/09/2021
• Today: 7/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: N/A
• Current Symbol: NASDAQ:FUSN
• CIK: 1805890
• Web: fusionpharma.com
• Phone: 289-799-0891
• Fax: N/A
• Employees: 101
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($1.42)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$94.90 million
• Net Margins: -4,136.55%
• Pretax Margin: -5,084.07%
• Return on Equity: -48.74%
• Return on Assets: -36.87%

Debt

• Debt-to-Equity Ratio: 0.21
• Current Ratio: 10.64
• Quick Ratio: 10.64

Sales & Book Value

• Annual Sales: $2.07 million
• Price / Sales: 885.53
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.07 per share
• Price / Book: 7.02

Miscellaneous

• Outstanding Shares: 85,060,000
• Free Float: 78,468,000
• Market Cap: $1.83 billion
• Optionable: Optionable
• Beta: -0.69